#BEGIN_DRUGCARD DB01196

# AHFS_Codes:
10:00.00

# ATC_Codes:
L01XX11

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Emcyt
Estracyt

# CAS_Registry_Number:
2998-57-4

# ChEBI_ID:
4868

# Chemical_Formula:
C23H31Cl2NO3

# Chemical_IUPAC_Name:
(1S,10R,11S,14S,15S)-14-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-trien-5-yl N,N-bis(2-chloroethyl)carbamate

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2063794

# Description:
A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties. [PubChem]

# Dosage_Forms:
Capsule	Oral

# Drug_Category:
Antineoplastic Agents
Antineoplastic Agents, Alkylating
Antineoplastic Agents, Hormonal
Radiation-Protective Agents

# Drug_Interactions:
Calcium Acetate	Calcium salts such as calcium acetate may decrease the absorption of estramustine. Interactions can be minimized by administering estramustine on an empty stomach, at least 1 hour before or 2 hours after the dose of an oral calcium supplement. Do not coadminister estramustine with food or milk. Monitor for decreased therapeutic effects of estramustine if administered with oral calcium supplements, food or milk.
Clodronate	Clodronate may increase the levels of estramustine.
Trastuzumab	Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
5.7

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Do not take with milk or milk products.
Take on an empty stomach.

# GenBank_ID:
Not Available

# Generic_Name:
Estramustine

# HET_ID:
Not Available

# Half_Life:
20 hours

# InChI_Identifier:
InChI=1S/C23H31Cl2NO3/c1-23-9-8-18-17-5-3-16(29-22(28)26(12-10-24)13-11-25)14-15(17)2-4-19(18)20(23)6-7-21(23)27/h3,5,14,18-21,27H,2,4,6-13H2,1H3/t18-,19-,20+,21+,23+/m1/s1

# InChI_Key:
InChIKey=FRPJXPJMRWBBIH-RBRWEJTLSA-N

# Indication:
For the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate

# KEGG_Compound_ID:
C11228

# KEGG_Drug_ID:
D04066

# LIMS_Drug_ID:
1196

# Mechanism_Of_Action:
Estramustine is a derivative of estradiol with a nitrogen mustard moiety. This gives it alkylating properties. In vivo, the nitrogen mustard component is active and can alklyate DNA and other cellular components (such as tubulin components) of rapidly dividing cells. This causes DNA strandbreaks or misscoding events. This leads to apoptosis and cell death. Also, due to the drugs estrogen component, it can bind more selectively to active estrogen receptors.

# Melting_Point:
104.5 Â°C

# Molecular_Weight_Avg:
440.403

# Molecular_Weight_Mono:
439.168099277

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA449507

# Pharmacology:
Estramustine is an antineoplastic agent indicated in the palliative treatment of patients with metastatic and/or progressive carcinoma of the prostate. Estramustine is a combination of estradiol with nitrogen mustard. In vivo, the nitrogen-mustard moiety becomes active and participates in alkylation of DNA or other cellular components.. This causes DNA damage in rapidly dividing cancerous cells leading to cell death and ideally, tumor shrinkage.

# Predicted_LogP_Hydrophobicity:
4.97

# Predicted_LogS:
-6.1

# Predicted_Water_Solubility:
3.85e-04 g/l

# Primary_Accession_No:
DB01196

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
http://www.rxlist.com/cgi/generic2/estramustine.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD00625

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]1([H])C3=CC=C(OC(=O)N(CCCl)CCCl)C=C3CC[C@@]21[H]

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Estramustin Sodium Phosphate
Estramustina [INN-Spanish]
Estramustine Sodium Phosphate
Estramustinum [INN-Latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:59 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Estramustine

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
1599956	Moraga D, Rivas-Berrios A, Farias G, Wallin M, Maccioni RB: Estramustine-phosphate binds to a tubulin binding domain on microtubule-associated proteins MAP-2 and tau. Biochim Biophys Acta. 1992 May 22;1121(1-2):97-103.
1647395	Stearns ME, Wang M, Sousa O: Evidence that estramustine binds MAP-1A to inhibit type IV collagenase secretion. J Cell Sci. 1991 Jan;98 ( Pt 1):55-63.
1908244	Friden B, Rutberg M, Deinum J, Wallin M: The effect of estramustine derivatives on microtubule assembly in vitro depends on the charge of the substituent. Biochem Pharmacol. 1991 Aug 8;42(5):997-1006.
2125244	Burns RG: Stoichiometry of estramustine phosphate binding to MAP2 measured by the disassembly of chick brain MAP2:tubulin microtubules. Cell Motil Cytoskeleton. 1990;17(3):167-73.
2679799	Falconer MM, Vielkind U, Brown DL: Association of acetylated microtubules, vimentin intermediate filaments, and MAP 2 during early neural differentiation in EC cell culture. Biochem Cell Biol. 1989 Sep;67(9):537-44.
6364362	Tew KD: The mechanism of action of estramustine. Semin Oncol. 1983 Sep;10(3 Suppl 3):21-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
MAP2

# Drug_Target_1_GenBank_ID_Gene:
U01828

# Drug_Target_1_GenBank_ID_Protein:
409875

# Drug_Target_1_GeneCard_ID:
MAP2

# Drug_Target_1_Gene_Name:
MAP2

# Drug_Target_1_Gene_Sequence:
>5481 bp
ATGGCAGATGAACGGAAAGACGAAGCAAAGGCACCTCACTGGACCTCAGCACCGCTAACA
GAGGCATCTGCACACTCACATCCACCTGAGATTAAGGATCAAGGCGGACGAGGGGAAGGA
CTTGTCCGAAGCGCCAATGGATTCCCATACAGGGAGGATGAAGAGGGTGCCTTTGGAGAG
CATGGGTCACAGGGCACCTATTCAAATACCAAAGAGAATGGGATCAACGGAGAGCTGACC
TCAGCTGACAGAGAAACAGCAGAGGAGGTGTCTGCAAGGATAGTTCAAGTAGTCACTGCT
GAGGCTGTAGCAGTCCTGAAAGCTGAACAAGAGAAAGAAGCTCAACATAAAGACCAGACT
GCAGCTCTGCCTTTAGCAGCTGAAGAAACAGCTAATCTGCCTCCTTCTCCACCCCCATCA
CCTGCCTCAGAACAGACTGTCACAGTGGAGGAAGATTTACTTACAGCCTCGAAGATGGAG
TTCCACGATCAACAGGAATTGACTCCCTCTACAGCTGAGCCTTCAGACCAGAAGGAAAAG
GAGTCAGAGAAGCAAAGTAGTCCTGGTGAAGACCTTAAACATGCTGCCTTAGTTTCTCAG
CCAGAGACAACTAAAACTTACCCTGATAAAAAGGACATGCAAGGCACAGAAGAAGAAAAA
GCACCCCTAGCTTTGTTTGGGCACACTCTTGTTGCCAGCCTGGAAGACATGAAACAGAAG
ACAGAACCAAGCCTTGTAGTACCTGGCATTGACCTCCCTAAAGAGCCTCCAACTCCAAAA
GAACAAAAGGACTGGTTCATCGAAATGCCAACGGAAGCAAAAAAGGATGAGTGGGGTTTA
GTTGCCCCCATATCTCCTGGCCCTCTGACTCCCATGAGGGAAAAAGATGTATTTGATGAT
ATCCCAAAATGGGAAGGGAAACAGTTTGATTCTCCCATGCCAAGTCCCTTTCAAGGGGGA
AGCTTCACTCTTCCTTTAGATGTCATGAAGAATGAAATAGTTACAGAAACATCGCCCTTT
GCCCCTGCCTTTTTACAGCCAGATGACAAAAAATCTCTGCAACAAACCAGTGGCCCAGCT
ACTGCCAAAGATAGTTTTAAAATTGAAGAGCCCCATGAGGCTAAACCTGACAAAATGGCA
GAAGCACCACCCTCAGAGGCAATGACCTTACCCAAAGATGCTCACATTCCAGTTGTAGAA
GAACATGTTATGGGGAAAGTTTTAGAGGAAGAAAAGGAGGCCATAAATCAAGAGACTGTG
CAGCAAAGGGATACTTTCACCCCCAGTGGACAGGAACCTATACTTACTGAAAAGGAAACT
GAGCTGAAGCTTGAAGAAAAAACCACCATTTCTGACAAAGAAGCTGTGCCAAAAGAGAGT
AAACCCCCAAAACCTGCAGATGAAGAAATAGGCATAATTCAGACCTCCACAGAGCACACT
TTCTCAGAACAGAAAGACCAAGAGCCTACCACAGATATGTTGAAACAGGACTCGTTCCCT
GTAAGTTTGGAGCAAGCAGTTACAGATTCAGCCATGACCTCTAAAACACTGGAGAAAGCC
ATGACCGAACCATCTGCATTAATTGAAAAGAGCTCAATTCAGGAACTTTTTGAAATGAGA
GTTGATGACAAAGATAAGATTGAAGGAGTTGGAGCTGCAACATCAGCTGAGCTTGATATG
CCATTTTATGAAGATAAATCAGGAATGTCCAAGTACTTTGAAACATCTGCCTTGAAAGAA
GAAGCAACAAAAAGCATTGAGCCAGGCAGTGATTACTATGAACTGAGTGACACTAGAGAA
AGTGTCCATGAGTCTATTGATACCATGTCTCCCATGCATAAAAATGGTGACAAGGAGTTT
CAAACAGGAAAAGAATCCCAGCCCAGTCCTCCAGCACAAGAAGCAGGGTACAGCACTCTC
GCACAGAGTTATCCATCAGATTTACCTGAAGAACCCAGTTCTCCTCAAGAAAGAATGTTC
ACTATTGATCCAAAAGTGTATGGAGAGAAAAGGGACCTCCACAGTAAGAATAAGGATGAT
TTGACCCTTAGCAGGAGTTTAGGACTTGGTGGTAGGTCTGCAATAGAACAAAGAAGCATG
TCAATCAATTTGCCGATGTCTTGCCTAGATTCCATAGCCCTTGGATTTAACTTTGGTCGG
GGACATGATCTTTCTCCTCTGGCTTCCGATATTCTAACCAACACTAGTGGAAGTATGGAT
GAAGGGGATGATTACCTTCCAGCCACCACACCTGCACTGGAGAAAGCCCCTTGCTTCCCT
GTAGAAAGCAAAGAGGAAGAACAGATAGAGAAAGTAAAAGCTACTGGAGAAGAAAGTACT
CAAGCGGAGATATCATGTGAGTCTCCTTTCCTAGCCAAAGATTTTTACAAAAATGGTACT
GTCATGGCACCTGACCTTCCTGAAATGCTAGATCTGGCAGGCACAAGGTCAAGATTGGCT
TCTGTGAGTGCAGATGCTGAGGTTGCCAGGAGGAAATCAGTCCCATCAGAGACTGTGGTT
GAGGATAGTCGTACTGGCTTGCCCCCGGTAACTGATGAAAACCATGTCATTGTAAAAACG
GACAGTCAGCTCGAAGACCTGGGCTACTGTGTGTTCAATAAGTACACAGTCCCATTGCCA
TCACCTGTTCAAGACAGTGAGAATTTATCAGGGGAGAGTGGTACCTTTTACGAAGGCACT
GATGATAAAGTTCGAAGAGATTTGGCCACAGACCTTTCACTGATTGAAGTGAAACTGGCA
GCAGCCGGAAGAGTCAAAGATGAGTTCAGTGTTGACAAAGAAGCATCCGCGCATATCTCT
GGTGACAAATCAGGACTGAGTAAGGAGTTTGACCAAGAGAAGAAAGCTAATGATAGGTTG
GATACTGTACTAGAAAAGAGTGAAGAACATGCTGATTCAAAAGAACATGCCAAGAAAACT
GAAGAGGCTGGTGATGAAATAGAAACATTCGGATTAGGAGTAACCTATGAGCAAGCTTTG
GCCAAAGATTTGTCAATACCAACAGATGCATCCTCTGAGAAAGCAGAGAAGGGTCTTAGT
TCAGTTCCAGAGATAGCTGAGGTAGAACCATCCAAAAAGGTGGAACAAGGTCTGGATTTT
GCTGTCCAGGGTCAACTAGATGTTAAAATTAGTGACTTTGGACAGATGGCTTCAGGGCTA
AACATAGATGATAGAAGGGCAACAGAGCTAAAACTTGAGGCTACACAGGACATGACCCCC
TCATCCAAAGCACCGCAGGAGGCAGATGCATTTATGGGTGTTGAGTCTGGCCACATGAAA
GAAGGCACTAAAGTTAGTGAGACAGAAGTCAAACAGAAGGTGGCCAAGCCTGACTTGGTG
CACCAGGAGGCTGTAGACAAGGAGGAGTCCTATGAATCTAGTGGTGAGCATGAAAGTCTC
ACCATGGAGTCCTTGAAAGCTGATGAGGGCAAGAAGGAAACATCTCCAGAATCATCTCTA
ATTCAAGATGAGATTGCCGTCAAATTGTCAGTGGAAATACCTTGCCCACCTGCTGTTTCA
GAGGCTGATTTAGCCACAGATGAGAGAGCTGATGTCCAGATGGAATTTATTCAGGGGCCA
AAAGAAGAAAGCAAAGAGACCCCAGATATATCCATCACGCCTTCTGATGTTGCAGAGCCA
TTGCATGAAACGATCGTATCTGAACCAGCAGAGATTCAGAGTGAGGAAGAAGAGATAGAA
GCCCAGGGAGAATATGATAAACTGCTCTTCCGCTCAGACACCCTTCAGATAACTGACCTG
GGTGTCTCAGGTGCCAGGGAGGAATTTGTGGAGACCTGCCCAAGTGAACACAAAGGAGTG
ATTGAGTCTGTTGTGACCATCGAGGATGATTTCATCACTGTAGTGCAAACCACAACTGAT
GAAGGGGAGTCAGGGTCCCACAGCGTGCGTTTTGCAGCCCTAGAGCAGCCTGAGGTGGAA
AGGAGACCATCTCCTCATGATGAAGAAGAGTTTGAAGTAGAAGAGGCAGCTGAAGCCCAG
GCAGAACCCAAAGATGGTTCCCCAGAGGCTCCAGCTTCCCCTGAGAGAGAAGAGGTTGCA
CTTTCTGAATATAAGACAGAAACCTATGACGATTACAAAGATGAGACCACCATTGACGAC
TCCATCATGGACGCTGACAGCCTCTGGGTGGACACTCAAGATGATGATAGGAGCATCATG
ACAGAACAGTTAGAAACTATTCCTAAAGAGGAGAAAGCTGAAAAGGAAGCTCGGAGATCA
TCTCTTGAGAAACATAGAAAAGAAAAGCCTTTTAAAACCGGGAGAGGCAGAATTTCCACT
CCTGAAAGAAAAGTAGCTAAAAAGGAACCTAGCACAGTCTCCAGAGATGAAGTGAGAAGG
AAAAAAGCAGTTTATAAGAAGGCTGAACTTGCTAAAAAAACAGAAGTTCAGGCCCACTCT
CCCTCCAGGAAATTCATTTTAAAACCTGCTATCAAATATACTAGACCAACTCATCTCTCC
TGTGTTAAGCGGAAAACCACAGCAGCAGGTGGGGAATCAGCTCTGGCTCCCAGTGTATTT
AAACAGGCAAAGGACAAAGTCTCTGACGGAGTAACCAAGAGCCCAGAAAAGCGCTCTTCT
CTCCCAAGACCTTCCTCCATTCTCCCTCCTCGGCGAGGTGTGTCAGGAGACAGAGATGAG
AATTCCTTCTCTCTCAACAGTTCTATCTCTTCTTCAGCACGGCGGACCACCAGGTCAGAG
CCAATTCGCAGAGCAGGAAAGAGTGGTACCTCAACACCCACTACCCCTGGGTCTACTGCC
ATCACTCCTGGCACCCCACCAAGTTATTCTTCACGCACACCAGGCACTCCTGGAACCCCT
AGCTATCCCAGGACCCCTCACACACCAGGAACCCCCAAGTCTGCCATCTTGGTGCCGAGT
GAGAAGAAGGTCGCCATCATACGTACTCCTCCAAAATCTCCTGCGACTCCCAAGCAGCTT
CGGCTTATTAACCAACCACTGCCAGACCTGAAGAATGTCAAATCCAAAATCGGATCAACA
GACAACATCAAATACCAGCCTAAAGGGGGGCAGGTACAAATTGTTACCAAGAAAATAGAC
CTAAGCCATGTGACATCCAAATGTGGCTCTCTGAAGAACATCGACAGGCCAGGTGGCGGA
CGTGTGAAAATTGAGAGTGTAAAACTAGATTTCAAGGAAAAGGTCCAAGCTAAAGTTGGT
TCTCTTGATAATGCTCATCATGTACCTGGAGGTGGTAATGTCAAGATTGACAGCCAAAAG
TTGAACTTCAGAGAGCATGCTAAAGCCCGTGTGGACCATGGGGCTGAGATCATTACACAG
TCCCCAGGCAGATCCAGCGTGGCATCACCCCGACGACTCAGCAATGTCTCCTCGTCTGGA
AGCATCAACCTGCTCGAATCTCCTCAGCTTGCCACTTTGGCTGAGGATGTCACTGCTGCA
CTCGCTAAGCAGGGCTTGTGA

# Drug_Target_1_General_Function:
Cell motility

# Drug_Target_1_General_References:
2455776	Kosik KS, Orecchio LD, Bakalis S, Duffy L, Neve RL: Partial sequence of MAP2 in the region of a shared epitope with Alzheimer neurofibrillary tangles. J Neurochem. 1988 Aug;51(2):587-98.
2481044	Dammerman M, Yen SH, Shafit-Zagardo B: Sequence of a human MAP-2 region sharing epitopes with Alzheimer neurofibrillary tangles. J Neurosci Res. 1989 Dec;24(4):487-95.
8294038	Albala JS, Kalcheva N, Shafit-Zagardo B: Characterization of the transcripts encoding two isoforms of human microtubule-associated protein-2 (MAP-2). Gene. 1993 Dec 22;136(1-2):377-8.

# Drug_Target_1_HGNC_ID:
HGNC:6839

# Drug_Target_1_HPRD_ID:
01140

# Drug_Target_1_ID:
1852

# Drug_Target_1_Locus:
2q34-q35

# Drug_Target_1_Molecular_Weight:
199540

# Drug_Target_1_Name:
Microtubule-associated protein 2

# Drug_Target_1_Number_of_Residues:
1827

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00418	Tubulin-binding
PF08377	MAP2_projctn

# Drug_Target_1_Protein_Sequence:
>Microtubule-associated protein 2
MADERKDEGKAPHWTSAPLTEASAHSHPPEIKDQGGAGEGLVRSANGFPYREDEEGAFGE
HGSQGTYSNTKENGINGELTSADRETAEEVSARIVQVVTAEAVAVLKGEQEKEAQHKDQT
AALPLAAEETANLPPSPPPSPASEQTVTVEEDLLTASKMEFHDQQELTPSTAEPSDQKEK
ESEKQSKPGEDLKHAALVSQPETTKTYPDKKDMQGTEEEKAPLALFGHTLVASLEDMKQK
TEPSLVVPGIDLPKEPPTPKEQKDWFIEMPTEAKKDEWGLVAPISPGPLTPMREKDVFDD
IPKWEGKQFDSPMPSPFQGGSFTLPLDVMKNEIVTETSPFAPAFLQPDDKKSLQQTSGPA
TAKDSFKIEEPHEAKPDKMAEAPPSEAMTLPKDAHIPVVEEHVMGKVLEEEKEAINQETV
QQRDTFTPSGQEPILTEKETELKLEEKTTISDKEAVPKESKPPKPADEEIGIIQTSTEHT
FSEQKDQEPTTDMLKQDSFPVSLEQAVTDSAMTSKTLEKAMTEPSALIEKSSIQELFEMR
VDDKDKIEGVGAATSAELDMPFYEDKSGMSKYFETSALKEEATKSIEPGSDYYELSDTRE
SVHESIDTMSPMHKNGDKEFQTGKESQPSPPAQEAGYSTLAQSYPSDLPEEPSSPQERMF
TIDPKVYGEKRDLHSKNKDDLTLSRSLGLGGRSAIEQRSMSINLPMSCLDSIALGFNFGR
GHDLSPLASDILTNTSGSMDEGDDYLPATTPALEKAPCFPVESKEEEQIEKVKATGEEST
QAEISCESPFLAKDFYKNGTVMAPDLPEMLDLAGTRSRLASVSADAEVARRKSVPSETVV
EDSRTGLPPVTDENHVIVKTDSQLEDLGYCVFNKYTVPLPSPVQDSENLSGESGTFYEGT
DDKVRRDLATDLSLIEVKLAAAGRVKDEFSVDKEASAHISGDKSGLSKEFDQEKKANDRL
DTVLEKSEEHADSKEHAKKTEEAGDEIETFGLGVTYEQALAKDLSIPTDASSEKAEKGLS
SVPEIAEVEPSKKVEQGLDFAVQGQLDVKISDFGQMASGLNIDDRRATELKLEATQDMTP
SSKAPQEADAFMGVESGHMKEGTKVSETEVKQKVAKPDLVHQEAVDKEESYESSGEHESL
TMESLKADEGKKETSPESSLIQDEIAVKLSVEIPCPPAVSEADLATDERADVQMEFIQGP
KEESKETPDISITPSDVAEPLHETIVSEPAEIQSEEEEIEAQGEYDKLLFRSDTLQITDL
GVSGAREEFVETCPSEHKGVIESVVTIEDDFITVVQTTTDEGESGSHSVRFAALEQPEVE
RRPSPHDEEEFEVEEAAEAQAEPKDGSPEAPASPEREEVALSEYKTETYDDYKDETTIDD
SIMDADSLWVDTQDDDRSIMTEQLETIPKEEKAEKEARRSSLEKHRKEKPFKTGRGRIST
PERKVAKKEPSTVSRDEVRRKKAVYKKAELAKKTEVQAHSPSRKFILKPAIKYTRPTHLS
CVKRKTTAAGGESALAPSVFKQAKDKVSDGVTKSPEKRSSLPRPSSILPPRRGVSGDRDE
NSFSLNSSISSSARRTTRSEPIRRAGKSGTSTPTTPGSTAITPGTPPSYSSRTPGTPGTP
SYPRTPHTPGTPKSAILVPSEKKVAIIRTPPKSPATPKQLRLINQPLPDLKNVKSKIGST
DNIKYQPKGGQVQIVTKKIDLSHVTSKCGSLKNIRHRPGGGRVKIESVKLDFKEKVQAKV
GSLDNAHHVPGGGNVKIDSQKLNFREHAKARVDHGAEIITQSPGRSSVASPRRLSNVSSS
GSINLLESPQLATLAEDVTAALAKQGL

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
The exact function of MAP2 is unknown but MAPs may stabilize the microtubules against depolymerization. They also seem to have a stiffening effect on microtubules

# Drug_Target_1_SwissProt_ID:
P11137

# Drug_Target_1_SwissProt_Name:
MAP2_HUMAN

# Drug_Target_1_Synonyms:
MAP 2
MAP-2

# Drug_Target_1_Theoretical_pI:
4.55

# Drug_Target_1_Transmembrane_Regions:
None

# Drug_Target_2_Cellular_Location:
Not Available

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
1647395	Stearns ME, Wang M, Sousa O: Evidence that estramustine binds MAP-1A to inhibit type IV collagenase secretion. J Cell Sci. 1991 Jan;98 ( Pt 1):55-63.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
MAP1A

# Drug_Target_2_GenBank_ID_Gene:
U38291

# Drug_Target_2_GenBank_ID_Protein:
1790878

# Drug_Target_2_GeneCard_ID:
MAP1A

# Drug_Target_2_Gene_Name:
MAP1A

# Drug_Target_2_Gene_Sequence:
>8418 bp
ATGGACGGCGTGGCTGAGTTCTCCGAGTATGTCTCTGAGACTGTGGACGTGCCATCCCCA
TNTGACCTACTAGAGCCCCCCACCTCAGGGGGCTTCCTCAAGCTCTCCAAGCCTTGTTGC
TACATCTTCCCAGGTGGTCGNGGGGACTCTGCCCTCTTTGCTGTCAATGGTTTCAACATC
CTGGTGGATGGTGGCTCTGATCGCAAGTCCTGTTTGTGGAAGCTGGTACGGNACTTGGAC
CGCATTGACTCGGTGCTACTCACACACATTGGGGCAGACAACCTGCCAGGCATCAATGGA
CTACTGCAGCGCAAAGTGGCAGAGCTAGAGGAGGAGCAGTCCCAGGGCTCTAGCAGTTAC
AGCGACTGGGTGAAGAACCTTATCTCTCCTGAGCTTGGAGTTGTCTTTTTCAACGTGCCT
GAGAAGCTGCGGCTTCCTGATGCCTCCCGGAAAGCCAAGCGTAGCATTGAGGAGGCCTGC
CTCACTCTGCAGCACTTAAACCGCCTGGGCATCCAGGCTGAGCCTCTATATCGTGTGGTC
AGCAATACCATTGAGCCACTGACCCTCTTCCACAAAATGGGTGTGGNCCGGCTGGACATG
TATGTCCTCAACCCTGTCAAGGACAGCAAGGAGATGCAGTTCCTCATGCANAAGTGGGCA
GGCAATAGTAAAGCCAAGACAGGCATCGTGCTGCCCAATGGGAAGGAGGCTGAGATCTCC
GTGCCCTACCTTACCTCTATCACTGCTCTGGTGGTCTGGCTACCAGCCAATCCCACTGAG
AAGATTGTGCGTGTGCTTTTTCCAGGAAATGCTCCCCAAAACAAGATCTTGGAGGGCCTA
GAAAAGCTTCGGCATCTGGACTTCCTGCGTTACCCTGTGGCCACGCAGAAGGACCTGGCT
TCTGGGGCTGTGCCTACCAACCTCAAGCCCAGCAAAATCAAACAGCGGGCTGATAGCAAG
GAGAGCCTCAAAGCCACTACCAAGACGNCCGTGAGCAAGTTGTCCACACGGGAGGAGGTG
GTAGAAGAGGGAGCCAAGGAGGCACGTTCAGAGCTGTCCAAGGAGTTATCCAAGACAGAG
AAGAAGGCNCAAGAGTCATCTGAGAAGCCCCCAGAGAAGCCTNCCAAGCCTGAGAGGGTG
AAGACAGAGTCAAGTGAGGCACTGNAGGCAGAGAAGCGAAAGCTGATCAAAGACAAGGTA
GGGAAAAAGCACCTTAAAGAAAAGATATCNAAGCTGGAAGAAAAAAAAGACAAGGAGANA
AAAGAGATCCCANAGGAGAGGAAAGAGCTCAAGAAGGATGAAGGAAGGAAGGAGGAGAAG
AAGGATNCCAAGAAGGAGGAGAAGAGGAAAGATACCAAACCTGAGCTCAAGAAGATTTCC
AAGCCAGACCTAAAGCCCTTTACTCCTGAGGTACGTAAGACCCTCTATAAAGCCAAGGTC
CCTGGAAGAGTCCNAATAGACAGGAGCCGTGCTATCCGTGGGGAGAAGGAGCTGTCTTCT
GAGCCCCAGACACCCCCAGCCCAGAAGGGAACTGTACCACTCCCAACCATCAGTGGGCAC
AGGGAGCTGGTCCTATCCTCACCAGAGGACCTCACACAGGACTTTGAGGAGATGAAGCGT
GAGGAGAGGGCTTTGCTGGCTGAACAAAGGGACACAGGACTAGGAGATAAGCCATTCCCT
CTAGACACTGCAGAGGAGGGACCCCCAAGTACAGCTATCCAGGGAACACCACCCTCTGTT
CCAGGGCTGGGACAAGAAGAACATGTGATGAAGGAGAAAGAGCTTGTCCCAGAGGTCCCT
GAGGAACAAGGCAGCAAGGACAGAGGCCTAGACTCTGGGGCTGAAACAGAGGAAGAGAAA
GATACCTGGGAGGAAAAGAAGCAGAGGGAAGCAGAGAGGCTCCCAGACAGAACAGAAGCC
AGAGAGGAAAGTGNACCTGNAGTAAAGGAGGATGTGATAGAAAAGGCTGAGTTAGAAGAA
ATGGAGGAGGTACACCCTTCAGATGAGGAGGAAGAGGACGCGACCCNANCTGAGGGTTTT
TACCCCNAACATATGCAGGAACCCTTGNAGGTAACTCCAAGGAGCCGGGAGGCTTTTGGG
GGTCGGGAATTGGGACTCCAGGGCAAGGCCCCTGAGAAGGAGACCTCGTTATTCCTAAGC
AGCCTGACCACACCTGCAGGAGCCACTGAGCATGTCTCTTACATCCAGGATGAGACAATC
CCTGGCTACTCAGAGACTGAGCAGACCATCTCAGATGAGGAGATCCATGATGAGCCGGAG
GAGCGCCCAGCTCCACCCAGATTTCATACAAGTACATATGACCTGCCCGGGCCTGAAGGT
GCTGGCCCATTCGAAGCCAGCCAACCTGCCGATAGTGCTGTTCCTGCTACCTCTGGCAAA
GTCTATGGAACGCCAGAGACTGAACTCACCTACCCCACTAACATAGTGGCTGCCCCTTTG
GCTGAAGAGGAACATGTGTCCTCGGCCACTTCAATCACTGAGTGTGACAAACTTTCTTCC
TTTGCCACATCAGTGGCTGAGGACCAATCTGTGGCCTCACTTACAGCTCCCCAGACAGAG
GAGACAGGCAAGAGCTCCCTGCTGCTTGACACAGTCACAAGCATCCCTTCCTCCCGTACT
GAAGCTACGCAGGGCTTGGACTATGTGCCATCAGCTGGTACCATCTCACCCACCTCCTCA
CTGGNAGAAGANAAGGGCTTCANATCACCACCCTGTGAGGACTTCTCTGTGACTGGGGAG
TCAGAGAAGAGAGGAGAGATCATAGGGAAAGGCTTGTCTGGAGAGAGAGCTGTGGAAGAG
GAAGAGGAGGAGACAGCAAACGTAGAGATGTCTGAGAAACTTTGNAGTCAATNTGGAACT
CCAGTGTTTAGTGCCCCTGGGNATGCCCTACATCCAGGAGAACCAGCCCTTGGAGAAGCA
GAGGAGCGGTGCCTTAGCCCAGATGACAGCACAGTGAAGATGGCTTCTCCTCCACCATCT
GGCCCACCCAGTGCCACCCACACACCCTTTCATCAGTCCCCAGTGGAAGAAAAGTCTGAG
CCCCAAGACTTCAAGGAGGCAGACTCCTGGGGAGACACTAAGCGCACACCAGGTGTGGGC
AAAGAAGATGCTGCTGAGGAGACAGTCAAGCCAGGGCCTGAAGAGGGCACACTAGAGAAG
GAAGAGAAAGTTCCTCCTCCCAGGAGCCCCCAGGCCCAGGAAGCACCTGTCAACATTGAT
GAGGGGCTTACAGGCTGTACCATTCAACTGTTGCCAGCACAGGATAAAGCAATAGTCTTT
GAGATTATGGAGGCAGGAGAGCCCACAGGCCCAATTCTGGGAGCAGAAGCCCTTCCCGGA
GGTTTGAGGACTTTACCCCAAGAACCTGGCAAACCTCAGAAAGATGAGGTGCTCAGATAT
CCTGACCGAAGCCTCTCTCCTGAAGATGNAGAATCCCTCTCTGTCCTCAGCGTGCCCTCC
CCAGACACTGNCANCCAAGAGCCTACCCCCAAGTCTCCCTGTGGNCTGANAGAACAGNAC
CTACACAAAGACCGGTGGNCAGAGGTATCTCCAGAAGACACCCAGTCACTTTCTCTGTCA
GAAGAGAGTCCCAGCAAGGAGACCTCCCTGGATGTCTCTTCTAAGCAGCTCTCTCCAGAA
AGCCTTGGCACCCTCCAGTTTGGGGAACTAAACCTTGGGAAGGAAGAAATGGGGCATCTG
ATGCAGGCCGAGGATACCTCTCACCACACAGCTCCCATGTCTGTTCCAGAGCCCCATGCA
GCCACAGCGTCACCTCCCACAGATGGGACAACTCGATACTCTGCACAGACAGACATCACA
GATGACAGCCTTGACAGGAAGTCACCTGCCAGCTCATTCTCTCACTCTACACCTTCAGGA
AATGGGAAGTACTTACCTGGGGCGATCACAAGCCCTGATGAACACATTCTGACANCTGAT
AGCTCCTTCTCCAAGAGTCCTGAGTCTTTGNCAGGCCCTGCCTTGGNGGACATTGCCATA
AAGTGGGAAGATAAAGTTCCAGGGTTGAAAGACAGAACCTCAGAACAGAAGAAGGAACCT
GAGCCAAAGGATGAAGTTTTACAGCAGAAAGACAAAACTCTGGAGCACAAGGAGGTGGTA
GAGCCGAAGGATACAGCCATCTATCAGAAAGATGAGGCTCTGCATGTAAAGAATGAGGCT
GTGAAACAGCAGGNTAAGGCTTTAGAACAAAAGGGCAGAGACTTAGAGCAANAAGACACA
GCCCTAGAACAGAAGGACAAGGCCCTGGAACCAAAAGACAAAGACTTAGAANAAAANGAC
AAGGCCCTGGAACAGAAGGATAAGATTCCAGNAGAGAAAGACAAAGCCTTAGAACAAAAG
GATACAGCCCTGGAACAGAAGGACAAGGCCCTGGAACCAAAAGATAAAGACTTGGAACAA
AAGGACAGGGTCCTAGAACAGAAGGAGAAGATCCCAGAAGAGAAAGACAAAGCCTTAGAT
CAAAAAGTCAGAAGTGTTGAACATAAGGCTCCGGAGGACACGGTCGCTGAAATGAAGGAC
AGAGACCTAGAACAGACAGACAAAGCCCCTGAACAGAAACACCAGGCCCAGGAACAAAAG
GATAAAGTCTCAGAAAAGAAGGATCAGGCCTTAGAACNCAAATACTGGGCTTTGGGACAG
AAGGATGAAGCCCTGGAACNAAACATTCAGGCTCTGGAAGAGAACCACCAAACTCAGGAG
CAGGAGAGCCTAGTGCAGGAGGATAAAACCAGGAAACCNAAGATGCTAGAGGAAAAATCC
CCAGAAAAGGTCAAGGCCATGGAAGAGAAGTTAGAAGCTCTTCTGGAGAAGACCNNAGCT
CTGGGCCTGGAAGAGAGCCTAGTGCAGGAGGGCAGGGCCAGAGAGCAGGAAGAAAAGTAC
TGGAGGGGGCAGGATGTGGTCCAGGAGTGTCAAGAAACATCTCCTNCCAGAGAGGAGCCG
GCTGGAGAACAGAAAGAGCTTNCCCCGGCATGGGAGGACACATCTCCTGAGCAGGACAAT
AGGTATTGGAGGGGCAGAGAGGATGTGTCCTTGGAACAGGACACATACTGGAGGGAGCTA
AGCTGTGAGCGGAAGGTCTGGTTCCCTCACGAGCTGGATGTCCAGGGGGCCCGCCCACAC
TACACTGANGAACGGGAAAGCACTTTCCTAGATGAGGGCCCAGATGATGAGCAAGAAGTA
CCCCTGCGGGAACACGCAACCCGGAGCCCCTGGGCCTCAGACTTCAAGGATTTCCAGGAA
TCCTCACCACAGAAGGGGCTAGAGGTGGAGCGCTGGCTTGCTGAATCACCAGTTGGGTTG
CCACCAGAGGAAGAGGACAAACTGACCCGCTCTCCCTTTGAGATCATCTCCCCTCCAGCT
TCCCCACCTGAGATGGTTGGACAAAGGGTTCCTTCAGCCCCAGGACAAGAGAGTCCTATC
CCAGACCCTAAGCTCATGCCACACATGAAGAATGAACCCACTACTCCCTCATGGCTGGCT
GANATCCCACCCTGGGTGCCCAAGGNCAGACCCCTCCCCNCTGCACCCCTCTCCCCAGCT
CCTGGTCCCCCCACACCTGCCCCGGAATCCCATACTCCTGCACCCTTCTCTTGGGGCACA
CCCGAGTATGACAGTGTGGTGGCTGCAGTACAGGAGGGGGCAGCTGAGTTGGAAGGTGGN
CCATACTCCCCCCTGGGGAAGGACTACCGCAAGGTTGANGGGGAAAGGGAAGAAGAAGGT
AGGGCTGAGGCTCCTGACAAAAGCTCACACAGNTCAAAGGTACCAGAGGCCAGGAAAAGC
CATGCCACCACGGAGCCTGAGCAGACTGAGCCGGAGCAGAGAGAGCCCACACCCTATCCT
GATGAGAGAAGCTTTCAGTATGCAGACATCTATGAGCAGATGATGCTTACTGGGCTTGGC
CCTGCATGCCCCACTAGAGAGCCTCCACTTGGAGCAGCTGGGGATTGGCCCCCATGCCTC
TCAACCAAGGAGGCAGCTGCCGGCCGAAACACATCTGCAGAGAAGGAGCTTTCATCTCCT
ATCTCACCCAAGAGCCTCCAGTCTGACACTCCAACCTTCAGCTATGCAGCCCTGGCAGGA
CCCACTGTACCCCCAAGGNCAGAGCCAGGGCCAAGTATGGAGCCCAGNCTCACCCCACCT
GCAGTTCCCCCCCGTGCTCCTATCCTGAGCAAAGGCCCAAGCCCCCCTCTTAATGGTAAC
ATCCTGAGCTGCAGCCCAGATAGGAGGTCCCCATCCCCCAAGGAATCAGGNCGGAGTCAC
TGGGATGACAGCACTAGTGACTCAGAACTGGAGAAGGGGGCTCGGGAACAGGCAGAAAAA
GAGGCCCAATCCCCAAGTCCTCCTCACCCCATTCCTATGGGGTCCCCCACATTATGGCCA
GAAACTGAGGCACATGTTAGCCCTCCCTTGGNCTCACACCTGGGGNCTGCCCGACCCAGT
CTGGACTTCCCTGCTTCAGCCTTTGGCTTCTCCTCATTGGANNCAGCTCCCCCACAGNTG
CCCTCTCCAGCTGAACCCCGCTCGGCACCCTGTGGCTCCCTTGCCTTCTCTGGGGATCGA
GCTCTGGCTCTGGCTCCAGGACCCCCCACCAGAACCCGGTATGATGAATACCTGGAAGTG
ACCAAGGCCCCCAGCCTGGATTCCTCACTGCCCCAGCTCCCATCACCCAGTTCTCCTGGG
GNCCCTCTCCTCTCCAATCTGCCACGACCTGCCTCACCAGCCCTGTCTGAGGGCTCCTCC
TCTGAGGCTACCACGCCTGTGATTTCAAGTGTGGCGGAGCGCTTCTCTCCAAGCCTTGAG
GCTGCAGAACAGGAGTCTGGAGAGCTGGACCCAGGAATGGAACCAGCTGCCCACAGNCTC
TGGGACCTCACTCCTCTGAGCCCAGCACCCCCAGCTTCACTGGACTTGGCCCTAGCTCCA
GCTCCAAGCCTGCCTGGAGACATGGGTGATGGCATCCTGCCGTGCCACCTGGAGTGCTCA
GAGGCAGCCACGGAGAAGCCAAGCCCCTTCCAGGTTCCCTCTGAGGATTGTGCAGCCAAT
GGCCCAACTGAAACCAGCCCTAACCCCCCAGNCCCTGCCCCAGCCAAGGCTGAAAATGAA
GAGGCTGCGGCTTNCCCTGCCTGGGAACGTGGGGCCTGGCCTGAAGGAGCTGAGAGGAGC
TCCCGGCCTGACACANTGCTCTCCCCTGAGCAGCCAGTGTGTCCTNCAGGGGGCTCCGGG
GGCCCACCCAGCAGTGCCTCTCCTGAGGTCGAAGCTGGGCCCCAGGGATGTNCCACTGAG
CCTCGGCCCCATCGTGGGGAGCTCTCCCCATCCTTCCTGAACCCACCTCTGCCCCCATCC
ATAGATGATAGGGACCTCTCAACTGAGGAAGTTCGGCTAGTAGGAAGAGGGGGGCGGCGC
CGGGTAGGGGGGCCAGGGACCACTGGGGNNCCATGNCCTGTGACTGATGAGACACCCCCN
ACATCAGCCAGTGACTCAGGCTCCTCACAGTCAGATTCTGATGTNCCGCCAGAAACTGAG
GAGTGTCCGTCCATCACAGCTGAGGCAGCCCTCGACTCAGATGAAGATGGAGACTTCCTA
CCTGTGGACAAANCTGGGGGTGTCAGTGGTACTCACCACCCCAGGCCTGGCCATGACCCA
CCTCCTCTCCCACAGCCAGACCNCCGCCCATCCCCTCCCCGCCCTGATGTGTGCATGGCT
GACCCCGAGGGGCTCAGNTCAGAGTCTGGGAGAGNAGAGAGGCTACGGNAGAAGGAAAAG
GTTCAGGGGCGAGTAGGGCGTAGGGCCCCAGGTAAGGACAAGCCAGTGTCCCCTGNACGG
CGTCTGGNTCTTCGGGGAAAACGCTCACCCACCCCTGGTAAAGGGTCTGNAGATCGAGTA
TCCCGGNCCCCANCTCGATCACGNAGTANCACAAGCCAGGTCACCCCAGCAGAGGAAAAG
GATGGACACAGCCCCATGTCCAAAGGNCTAGTCAATGGACTCAAGGCAGGACCANTGGCC
TTGAGTTCCAAGGGCAGCTCTGGTGCCCCTGTATATGTGGATCTCGCCTACATCCCGAAT
CATTGGAGTGGCAAGACTGCTGACCTNGACTTCTTCCGTCGAGTGCGTGCATCCTACTAT
GTGGTCAGTGGGAATGACCCTGCCAATGGCGAGCCAAGCCGGGCTGTGCTGGATGCCCTG
CTGGAGGGCAAGGCCCAGTGGGGGGAGAATCTTCAGGTGAAGGTGACTCTGATCCCTACT
CATGACACGGAGGTGACTCGTGAGTGGTACCAACAAACTCATGAGCAGCAGCAACAACTG
AATGTCCTGGTCCTGGCTAGCAGCAGCACCGTGGTGATGCAGGATGAGTCCTTCCCTGCC
TGCAAGATTGAGTTCTGA

# Drug_Target_2_General_Function:
Replication, recombination and repair

# Drug_Target_2_General_References:
7629894	Fukuyama R, Rapoport SI: Brain-specific expression of human microtubule-associated protein 1A (MAP1A) gene and its assignment to human chromosome 15. J Neurosci Res. 1995 Apr 15;40(6):820-5.
8812494	Fink JK, Jones SM, Esposito C, Wilkowski J: Human microtubule-associated protein 1a (MAP1A) gene: genomic organization, cDNA sequence, and developmental- and tissue-specific expression. Genomics. 1996 Aug 1;35(3):577-85.

# Drug_Target_2_HGNC_ID:
HGNC:6835

# Drug_Target_2_HPRD_ID:
02549

# Drug_Target_2_ID:
2107

# Drug_Target_2_Locus:
15q13-qter

# Drug_Target_2_Molecular_Weight:
305018

# Drug_Target_2_Name:
Microtubule-associated protein 1A

# Drug_Target_2_Number_of_Residues:
2805

# Drug_Target_2_PDB_ID:
Not Available

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
Not Available

# Drug_Target_2_Protein_Sequence:
>Microtubule-associated protein 1A
MDGVAEFSEYVSETVDVPSPFDLLEPPTSGGFLKLSKPCCYIFPGGRGDSALFAVNGFNI
LVDGGSDRKSCFWKLVRHLDRIDSVLLTHIGADNLPGINGLLQRKVAELEEEQSQGSSSY
SDWVKNLISPELGVVFFNVPEKLRLPDASRKAKRSIEEACLTLQHLNRLGIQAEPLYRVV
SNTIEPLTLFHKMGVGRLDMYVLNPVKDSKEMQFLMQKWAGNSKAKTGIVLPNGKEAEIS
VPYLTSITALVVWLPANPTEKIVRVLFPGNAPQNKILEGLEKLRHLDFLRYPVATQKDLA
SGAVPTNLKPSKIKQRADSKESLKATTKTAVSKLAKREEVVEEGAKEARSELAKELAKTE
KKAKESSEKPPEKPAKPERVKTESSEALKAEKRKLIKDKVGKKHLKEKISKLEEKKDKEK
KEIKKERKELKKDEGRKEEKKDAKKEEKRKDTKPELKKISKPDLKPFTPEVRKTLYKAKV
PGRVKIDRSRAIRGEKELSSEPQTPPAQKGTVPLPTISGHRELVLSSPEDLTQDFEEMKR
EERALLAEQRDTGLGDKPFPLDTAEEGPPSTAIQGTPPSVPGLGQEEHVMKEKELVPEVP
EEQGSKDRGLDSGAETEEEKDTWEEKKQREAERLPDRTEAREESEPEVKEDVIEKAELEE
MEEVHPSDEEEEDATKAEGFYQKHMQEPLKVTPRSREAFGGRELGLQGKAPEKETSLFLS
SLTTPAGATEHVSYIQDETIPGYSETEQTISDEEIHDEPEERPAPPRFHTSTYDLPGPEG
AGPFEASQPADSAVPATSGKVYGTPETELTYPTNIVAAPLAEEEHVSSATSITECDKLSS
FATSVAEDQSVASLTAPQTEETGKSSLLLDTVTSIPSSRTEATQGLDYVPSAGTISPTSS
LEEDKGFKSPPCEDFSVTGESEKRGEIIGKGLSGERAVEEEEEETANVEMSEKLCSQYGT
PVFSAPGHALHPGEPALGEAEERCLSPDDSTVKMASPPPSGPPSATHTPFHQSPVEEKSE
PQDFQEADSWGDTKRTPGVGKEDAAEETVKPGPEEGTLEKEEKVPPPRSPQAQEAPVNID
EGLTGCTIQLLPAQDKAIVFEIMEAGEPTGPILGAEALPGGLRTLPQEPGKPQKDEVLRY
PDRSLSPEDAESLSVLSVPSPDTANQEPTPKSPCGLTEQYLHKDRWPEVSPEDTQSLSLS
EESPSKETSLDVSSKQLSPESLGTLQFGELNLGKEEMGHLMQAEDTSHHTAPMSVPEPHA
ATASPPTDGTTRYSAQTDITDDSLDRKSPASSFSHSTPSGNGKYLPGAITSPDEHILTPD
SSFSKSPESLPGPALEDIAIKWEDKVPGLKDRTSEQKKEPEPKDEVLQQKDKTLEHKEVV
EPKDTAIYQKDEALHVKNEAVKQQDKALEQKGRDLEQKDTALEQKDKALEPKDKDLEEKD
KALEQKDKIPEEKDKALEQKDTALEQKDKALEPKDKDLEQKDRVLEQKEKIPEEKDKALD
QKVRSVEHKAPEDTVAEMKDRDLEQTDKAPEQKHQAQEQKDKVSEKKDQALEQKYWALGQ
KDEALEQNIQALEENHQTQEQESLVQEDKTRKPKMLEEKSPEKVKAMEEKLEALLEKTKA
LGLEESLVQEGRAREQEEKYWRGQDVVQEWQETSPTREEPAGEQKELAPAWEDTSPEQDN
RYWRGREDVALEQDTYWRELSCERKVWFPHELDGQGARPHYTEERESTFLDEGPDDEQEV
PLREHATRSPWASDFKDFQESSPQKGLEVERWLAESPVGLPPEEEDKLTRSPFEIISPPA
SPPEMVGQRVPSAPGQESPIPDPKLMPHMKNEPTTPSWLADIPPWVPKDRPLPPAPLSPA
PGPPTPAPESHTPAPFSWGTPEYDSVVAAVQEGAAELEGGPYSPLGKDYRKVXGEREEEG
RAEAPDKSSHXSKVPEARKSHATTEPEQTEPEQREPTPYPDERSFQYADIYEQMMLTGLG
PACPTREPPLGAAGDWPPCLSTKEAAAGRNTSAEKELSSPISPKSLQSDTPTFSYAALAG
PTVPPRXEPGPSMEPSLTPPAVPPRAPILSKGPSPPLNGNILSCSPDRRSPSPKESGRSH
WDDSTSDSELEKGAREQAEKEAQSPSPPHPIPMGSPTLWPETEAHVSPPLXSHLGXARPS
LDFPASAFGFSSLEXAPPQXPSPAEPRSAPCGSLAFSGDRALALAPGPPTRTRYDEYLEV
TKAPSLDSSLPQLPSPSSPGXPLLSNLPRPASPALSEGSSSEATTPVISSVAERFSPSLE
AAEQESGELDPGMEPAAHXLWDLTPLSPAPPASLDLALAPAPSLPGDMGDGILPCHLECS
EAATEKPSPFQVPSEDCAANGPTETSPNPPXPAPAKAENEEAAAXPAWERGAWPEGAERS
SRPDTXLSPEQPVCPXGGSGGPPSSASPEVEAGPQGCXTEPRPHRGELSPSFLNPPLPPS
IDDRDLSTEEVRLVGRGGRRRVGGPGTTGXPXPVTDETPPTSASDSGSSQSDSDVPPETE
ECPSITAEAALDSDEDGDFLPVDKXGGVSGTHHPRPGHDPPPLPQPDXRPSPPRPDVCMA
DPEGLSSESGRXERLRXKEKVQGRVGRRAPGKDKPVSPXRRLXLRGKRSPTPGKGSXDRV
SRXPXRSRSXTSQVTPAEEKDGHSPMSKGLVNGLKAGPXALSSKGSSGAPVYVDLAYIPN
HWSGKTADLDFFRRVRASYYVVSGNDPANGEPSRAVLDALLEGKAQWGENLQVKVTLIPT
HDTEVTREWYQQTHEQQQQLNVLVLASSSTVVMQDESFPACKIEF

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
None

# Drug_Target_2_Specific_Function:
Structural protein involved in the filamentous cross- bridging between microtubules and other skeletal elements

# Drug_Target_2_SwissProt_ID:
P78559

# Drug_Target_2_SwissProt_Name:
MAP1A_HUMAN

# Drug_Target_2_Synonyms:
MAP 1A
Proliferation-related protein p80

# Drug_Target_2_Theoretical_pI:
4.57

# Drug_Target_2_Transmembrane_Regions:
None

# Drug_Target_3_Cellular_Location:
Nucleus

# Drug_Target_3_Chromosome_Location:
Not Available

# Drug_Target_3_Drug_References:
3314674	Ferno M, Borg A, Ingvar C, Jonsson PE: Estrogen receptor and binding site for estramustine in metastatic malignant melanoma. Anticancer Res. 1987 Jul-Aug;7(4B):741-3.
3989343	Yoshizumi N: [The effects of site-directed chemotherapy due to E2 as a drug carrier to the human endometrial adenocarcinoma cells in vitro] Nippon Sanka Fujinka Gakkai Zasshi. 1985 Apr;37(4):637-45.
6364362	Tew KD: The mechanism of action of estramustine. Semin Oncol. 1983 Sep;10(3 Suppl 3):21-6.
7703721	von Schoultz E, Carlstrom K, Henriksson R, Lagerlof B, Hansson J: Estramustine binding protein in primary tumours and metastases of malignant melanoma. Melanoma Res. 1994 Dec;4(6):401-5.

# Drug_Target_3_Essentiality:
Non-Essential

# Drug_Target_3_GenAtlas_ID:
ESR1

# Drug_Target_3_GenBank_ID_Gene:
X03635

# Drug_Target_3_GenBank_ID_Protein:
31234

# Drug_Target_3_GeneCard_ID:
ESR1

# Drug_Target_3_Gene_Name:
ESR1

# Drug_Target_3_Gene_Sequence:
>1788 bp
ATGACCATGACCCTCCACACCAAAGCATCTGGGATGGCCCTACTGCATCAGATCCAAGGG
AACGAGCTGGAGCCCCTGAACCGTCCGCAGCTCAAGATCCCCCTGGAGCGGCCCCTGGGC
GAGGTGTACCTGGACAGCAGCAAGCCCGCCGTGTACAACTACCCCGAGGGCGCCGCCTAC
GAGTTCAACGCCGCGGCCGCCGCCAACGCGCAGGTCTACGGTCAGACCGGCCTCCCCTAC
GGCCCCGGGTCTGAGGCTGCGGCGTTCGGCTCCAACGGCCTGGGGGGTTTCCCCCCACTC
AACAGCGTGTCTCCGAGCCCGCTGATGCTACTGCACCCGCCGCCGCAGCTGTCGCCTTTC
CTGCAGCCCCACGGCCAGCAGGTGCCCTACTACCTGGAGAACGAGCCCAGCGGCTACACG
GTGCGCGAGGCCGGCCCGCCGGCATTCTACAGGCCAAATTCAGATAATCGACGCCAGGGT
GGCAGAGAAAGATTGGCCAGTACCAATGACAAGGGAAGTATGGCTATGGAATCTGCCAAG
GAGACTCGCTACTGTGCAGTGTGCAATGACTATGCTTCAGGCTACCATTATGGAGTCTGG
TCCTGTGAGGGCTGCAAGGCCTTCTTCAAGAGAAGTATTCAAGGACATAACGACTATATG
TGTCCAGCCACCAACCAGTGCACCATTGATAAAAACAGGAGGAAGAGCTGCCAGGCCTGC
CGGCTCCGCAAATGCTACGAAGTGGGAATGATGAAAGGTGGGATACGAAAAGACCGAAGA
GGAGGGAGAATGTTGAAACACAAGCGCCAGAGAGATGATGGGGAGGGCAGGGGTGAAGTG
GGGTCTGCTGGAGACATGAGAGCTGCCAACCTTTGGCCAAGCCCGCTCATGATCAAACGC
TCTAAGAAGAACAGCCTGGCCTTGTCCCTGACGGCCGACCAGATGGTCAGTGCCTTGTTG
GATGCTGAGCCCCCCATACTCTATTCCGAGTATGATCCTACCAGACCCTTCAGTGAAGCT
TCGATGATGGGCTTACTGACCAACCTGGCAGACAGGGAGCTGGTTCACATGATCAACTGG
GCGAAGAGGGTGCCAGGCTTTGTGGATTTGACCCTCCATGATCAGGTCCACCTTCTAGAA
TGTGCCTGGCTAGAGATCCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGTG
AAGCTACTGTTTGCTCCTAACTTGCTCTTGGACAGGAACCAGGGAAAATGTGTAGAGGGC
ATGGTGGAGATCTTCGACATGCTGCTGGCTACATCATCTCGGTTCCGCATGATGAATCTG
CAGGGAGAGGAGTTTGTGTGCCTCAAATCTATTATTTTGCTTAATTCTGGAGTGTACACA
TTTCTGTCCAGCACCCTGAAGTCTCTGGAAGAGAAGGACCATATCCACCGAGTCCTGGAC
AAGATCACAGACACTTTGATCCACCTGATGGCCAAGGCAGGCCTGACCCTGCAGCAGCAG
CACCAGCGGCTGGCCCAGCTCCTCCTCATCCTCTCCCACATCAGGCACATGAGTAACAAA
GGCATGGAGCATCTGTACAGCATGAAGTGCAAGAACGTGGTGCCCCTCTATGACCTGCTG
CTGGAGATGCTGGACGCCCACCGCCTACATGCGCCCACTAGCCGTGGAGGGGCATCCGTG
GAGGAGACGGACCAAAGCCACTTGGCCACTGCGGGCTCTACTTCATCGCATTCCTTGCAA
AAGTATTACATCACGGGGGAGGCAGAGGGTTTCCCTGCCACAGTCTGA

# Drug_Target_3_General_Function:
Involved in transcription factor activity

# Drug_Target_3_General_References:
10359819	Montano MM, Ekena K, Delage-Mourroux R, Chang W, Martini P, Katzenellenbogen BS: An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens. Proc Natl Acad Sci U S A. 1999 Jun 8;96(12):6947-52.
10428798	Rogatsky I, Trowbridge JM, Garabedian MJ: Potentiation of human estrogen receptor alpha transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem. 1999 Aug 6;274(32):22296-302.
10567404	Lee SK, Anzick SL, Choi JE, Bubendorf L, Guan XY, Jung YK, Kallioniemi OP, Kononen J, Trent JM, Azorsa D, Jhun BH, Cheong JH, Lee YC, Meltzer PS, Lee JW: A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J Biol Chem. 1999 Nov 26;274(48):34283-93.
10619354	Schubert EL, Lee MK, Newman B, King MC: Single nucleotide polymorphisms (SNPs) in the estrogen receptor gene and breast cancer susceptibility. J Steroid Biochem Mol Biol. 1999 Nov;71(1-2):21-7.
11113208	Sauve F, McBroom LD, Gallant J, Moraitis AN, Labrie F, Giguere V: CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol. 2001 Jan;21(1):343-53.
11971969	Shao W, Halachmi S, Brown M: ERAP140, a conserved tissue-specific nuclear receptor coactivator. Mol Cell Biol. 2002 May;22(10):3358-72.
12415108	Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14783-8. Epub 2002 Nov 1.
14574404	Mungall AJ, Palmer SA, Sims SK, Edwards CA, Ashurst JL, Wilming L, Jones MC, Horton R, Hunt SE, Scott CE, Gilbert JG, Clamp ME, Bethel G, Milne S, Ainscough R, Almeida JP, Ambrose KD, Andrews TD, Ashwell RI, Babbage AK, Bagguley CL, Bailey J, Banerjee R, Barker DJ, Barlow KF, Bates K, Beare DM, Beasley H, Beasley O, Bird CP, Blakey S, Bray-Allen S, Brook J, Brown AJ, Brown JY, Burford DC, Burrill W, Burton J, Carder C, Carter NP, Chapman JC, Clark SY, Clark G, Clee CM, Clegg S, Cobley V, Collier RE, Collins JE, Colman LK, Corby NR, Coville GJ, Culley KM, Dhami P, Davies J, Dunn M, Earthrowl ME, Ellington AE, Evans KA, Faulkner L, Francis MD, Frankish A, Frankland J, French L, Garner P, Garnett J, Ghori MJ, Gilby LM, Gillson CJ, Glithero RJ, Grafham DV, Grant M, Gribble S, Griffiths C, Griffiths M, Hall R, Halls KS, Hammond S, Harley JL, Hart EA, Heath PD, Heathcott R, Holmes SJ, Howden PJ, Howe KL, Howell GR, Huckle E, Humphray SJ, Humphries MD, Hunt AR, Johnson CM, Joy AA, Kay M, Keenan SJ, Kimberley AM, King A, Laird GK, Langford C, Lawlor S, Leongamornlert DA, Leversha M, Lloyd CR, Lloyd DM, Loveland JE, Lovell J, Martin S, Mashreghi-Mohammadi M, Maslen GL, Matthews L, McCann OT, McLaren SJ, McLay K, McMurray A, Moore MJ, Mullikin JC, Niblett D, Nickerson T, Novik KL, Oliver K, Overton-Larty EK, Parker A, Patel R, Pearce AV, Peck AI, Phillimore B, Phillips S, Plumb RW, Porter KM, Ramsey Y, Ranby SA, Rice CM, Ross MT, Searle SM, Sehra HK, Sheridan E, Skuce CD, Smith S, Smith M, Spraggon L, Squares SL, Steward CA, Sycamore N, Tamlyn-Hall G, Tester J, Theaker AJ, Thomas DW, Thorpe A, Tracey A, Tromans A, Tubby B, Wall M, Wallis JM, West AP, White SS, Whitehead SL, Whittaker H, Wild A, Willey DJ, Wilmer TE, Wood JM, Wray PW, Wyatt JC, Young L, Younger RM, Bentley DR, Coulson A, Durbin R, Hubbard T, Sulston JE, Dunham I, Rogers J, Beck S: The DNA sequence and analysis of human chromosome 6. Nature. 2003 Oct 23;425(6960):805-11.
1577818	Reese JC, Katzenellenbogen BS: Characterization of a temperature-sensitive mutation in the hormone binding domain of the human estrogen receptor. Studies in cell extracts and intact cells and their implications for hormone-dependent transcriptional activation. J Biol Chem. 1992 May 15;267(14):9868-73.
2247153	Schwabe JW, Neuhaus D, Rhodes D: Solution structure of the DNA-binding domain of the oestrogen receptor. Nature. 1990 Nov 29;348(6300):458-61.
2792078	Tora L, Mullick A, Metzger D, Ponglikitmongkol M, Park I, Chambon P: The cloned human oestrogen receptor contains a mutation which alters its hormone binding properties. EMBO J. 1989 Jul;8(7):1981-6.
3753802	Greene GL, Gilna P, Waterfield M, Baker A, Hort Y, Shine J: Sequence and expression of human estrogen receptor complementary DNA. Science. 1986 Mar 7;231(4742):1150-4.
3754034	Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, Chambon P: Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature. 1986 Mar 13-19;320(6058):134-9.
7476978	Joel PB, Traish AM, Lannigan DA: Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol Endocrinol. 1995 Aug;9(8):1041-52.
7539106	Arnold SF, Obourn JD, Jaffe H, Notides AC: Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol. 1995 Jan;9(1):24-33.
7838153	Arnold SF, Obourn JD, Jaffe H, Notides AC: Serine 167 is the major estradiol-induced phosphorylation site on the human estrogen receptor. Mol Endocrinol. 1994 Sep;8(9):1208-14.
7916651	Pfeffer U, Fecarotta E, Castagnetta L, Vidali G: Estrogen receptor variant messenger RNA lacking exon 4 in estrogen-responsive human breast cancer cell lines. Cancer Res. 1993 Feb 15;53(4):741-3.
8221895	Schwabe JW, Chapman L, Finch JT, Rhodes D: The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell. 1993 Nov 5;75(3):567-78.
8600466	Pink JJ, Wu SQ, Wolf DM, Bilimoria MM, Jordan VC: A novel 80 kDa human estrogen receptor containing a duplication of exons 6 and 7. Nucleic Acids Res. 1996 Mar 1;24(5):962-9.
8961262	McInerney EM, Ince BA, Shapiro DJ, Katzenellenbogen BS: A transcriptionally active estrogen receptor mutant is a novel type of dominant negative inhibitor of estrogen action. Mol Endocrinol. 1996 Dec;10(12):1519-26.
9195227	Anderson TI, Wooster R, Laake K, Collins N, Warren W, Skrede M, Elles R, Tveit KM, Johnston SR, Dowsett M, Olsen AO, Moller P, Stratton MR, Borresen-Dale AL: Screening for ESR mutations in breast and ovarian cancer patients. Hum Mutat. 1997;9(6):531-6.
9338790	Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M: Molecular basis of agonism and antagonism in the oestrogen receptor. Nature. 1997 Oct 16;389(6652):753-8.
9600906	Tanenbaum DM, Wang Y, Williams SP, Sigler PB: Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proc Natl Acad Sci U S A. 1998 May 26;95(11):5998-6003.
9619507	Maalouf GJ, Xu W, Smith TF, Mohr SC: Homology model for the ligand-binding domain of the human estrogen receptor. J Biomol Struct Dyn. 1998 Apr;15(5):841-51.
9875847	Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL: The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell. 1998 Dec 23;95(7):927-37.

# Drug_Target_3_HGNC_ID:
HGNC:3467

# Drug_Target_3_HPRD_ID:
00589

# Drug_Target_3_ID:
136

# Drug_Target_3_Locus:
6q25.1

# Drug_Target_3_Molecular_Weight:
66217

# Drug_Target_3_Name:
Estrogen receptor

# Drug_Target_3_Number_of_Residues:
595

# Drug_Target_3_PDB_ID:
1R5K

# Drug_Target_3_Pathway:
Tamoxifen Pathway	SMP00471

# Drug_Target_3_Pfam_Domain_Function:
PF00104	Hormone_recep
PF00105	zf-C4
PF02159	Oest_recep

# Drug_Target_3_Protein_Sequence:
>Estrogen receptor
MTMTLHTKASGMALLHQIQGNELEPLNRPQLKIPLERPLGEVYLDSSKPAVYNYPEGAAY
EFNAAAAANAQVYGQTGLPYGPGSEAAAFGSNGLGGFPPLNSVSPSPLMLLHPPPQLSPF
LQPHGQQVPYYLENEPSGYTVREAGPPAFYRPNSDNRRQGGRERLASTNDKGSMAMESAK
ETRYCAVCNDYASGYHYGVWSCEGCKAFFKRSIQGHNDYMCPATNQCTIDKNRRKSCQAC
RLRKCYEVGMMKGGIRKDRRGGRMLKHKRQRDDGEGRGEVGSAGDMRAANLWPSPLMIKR
SKKNSLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINW
AKRVPGFVDLTLHDQVHLLECAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKCVEG
MVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLD
KITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPLYDLL
LEMLDAHRLHAPTSRGGASVEETDQSHLATAGSTSSHSLQKYYITGEAEGFPATV

# Drug_Target_3_Reaction:
Not Available

# Drug_Target_3_Signals:
None

# Drug_Target_3_Specific_Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues

# Drug_Target_3_SwissProt_ID:
P03372

# Drug_Target_3_SwissProt_Name:
ESR1_HUMAN

# Drug_Target_3_Synonyms:
ER
ER-alpha
Estradiol receptor

# Drug_Target_3_Theoretical_pI:
8.14

# Drug_Target_3_Transmembrane_Regions:
None

# Drug_Target_4_Cellular_Location:
Nucleus

# Drug_Target_4_Chromosome_Location:
Not Available

# Drug_Target_4_Drug_References:
14755680	Ho SM: Estrogens and anti-estrogens: key mediators of prostate carcinogenesis and new therapeutic candidates. J Cell Biochem. 2004 Feb 15;91(3):491-503.

# Drug_Target_4_Essentiality:
Non-Essential

# Drug_Target_4_GenAtlas_ID:
ESR2

# Drug_Target_4_GenBank_ID_Gene:
AB006590

# Drug_Target_4_GenBank_ID_Protein:
2911152

# Drug_Target_4_GeneCard_ID:
ESR2

# Drug_Target_4_Gene_Name:
ESR2

# Drug_Target_4_Gene_Sequence:
>1593 bp
ATGGATATAAAAAACTCACCATCTAGCCTTAATTCTCCTTCCTCCTACAACTGCAGTCAA
TCCATCTTACCCCTGGAGCACGGCTCCATATACATACCTTCCTCCTATGTAGACAGCCAC
CATGAATATCCAGCCATGACATTCTATAGCCCTGCTGTGATGAATTACAGCATTCCCAGC
AATGTCACTAACTTGGAAGGTGGGCCTGGTCGGCAGACCACAAGCCCAAATGTGTTGTGG
CCAACACCTGGGCACCTTTCTCCTTTAGTGGTCCATCGCCAGTTATCACATCTGTATGCG
GAACCTCAAAAGAGTCCCTGGTGTGAAGCAAGATCGCTAGAACACACCTTACCTGTAAAC
AGAGAGACACTGAAAAGGAAGGTTAGTGGGAACCGTTGCGCCAGCCCTGTTACTGGTCCA
GGTTCAAAGAGGGATGCTCACTTCTGCGCTGTCTGCAGCGATTACGCATCGGGATATCAC
TATGGAGTCTGGTCGTGTGAAGGATGTAAGGCCTTTTTTAAAAGAAGCATTCAAGGACAT
AATGATTATATTTGTCCAGCTACAAATCAGTGTACAATCGATAAAAACCGGCGCAAGAGC
TGCCAGGCCTGCCGACTTCGGAAGTGTTACGAAGTGGGAATGGTGAAGTGTGGCTCCCGG
AGAGAGAGATGTGGGTACCGCCTTGTGCGGAGACAGAGAAGTGCCGACGAGCAGCTGCAC
TGTGCCGGCAAGGCCAAGAGAAGTGGCGGCCACGCGCCCCGAGTGCGGGAGCTGCTGCTG
GACGCCCTGAGCCCCGAGCAGCTAGTGCTCACCCTCCTGGAGGCTGAGCCGCCCCATGTG
CTGATCAGCCGCCCCAGTGCGCCCTTCACCGAGGCCTCCATGATGATGTCCCTGACCAAG
TTGGCCGACAAGGAGTTGGTACACATGATCAGCTGGGCCAAGAAGATTCCCGGCTTTGTG
GAGCTCAGCCTGTTCGACCAAGTGCGGCTCTTGGAGAGCTGTTGGATGGAGGTGTTAATG
ATGGGGCTGATGTGGCGCTCAATTGACCACCCCGGCAAGCTCATCTTTGCTCCAGATCTT
GTTCTGGACAGGGATGAGGGGAAATGCGTAGAAGGAATTCTGGAAATCTTTGACATGCTC
CTGGCAACTACTTCAAGGTTTCGAGAGTTAAAACTCCAACACAAAGAATATCTCTGTGTC
AAGGCCATGATCCTGCTCAATTCCAGTATGTACCCTCTGGTCACAGCGACCCAGGATGCT
GACAGCAGCCGGAAGCTGGCTCACTTGCTGAACGCCGTGACCGATGCTTTGGTTTGGGTG
ATTGCCAAGAGCGGCATCTCCTCCCAGCAGCAATCCATGCGCCTGGCTAACCTCCTGATG
CTCCTGTCCCACGTCAGGCATGCGAGTAACAAGGGCATGGAACATCTGCTCAACATGAAG
TGCAAAAATGTGGTCCCAGTGTATGACCTGCTGCTGGAGATGCTGAATGCCCACGTGCTT
CGCGGGTGCAAGTCCTCCATCACGGGGTCCGAGTGCAGCCCGGCAGAGGACAGTAAAAGC
AAAGAGGGCTCCCAGAACCCACAGTCTCAGTGA

# Drug_Target_4_General_Function:
Involved in transcription factor activity

# Drug_Target_4_General_References:
10681503	Caira F, Antonson P, Pelto-Huikko M, Treuter E, Gustafsson JA: Cloning and characterization of RAP250, a novel nuclear receptor coactivator. J Biol Chem. 2000 Feb 25;275(8):5308-17.
10964723	Li LC, Yeh CC, Nojima D, Dahiya R: Cloning and characterization of human estrogen receptor beta promoter. Biochem Biophys Res Commun. 2000 Aug 28;275(2):682-9.
11113208	Sauve F, McBroom LD, Gallant J, Moraitis AN, Labrie F, Giguere V: CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol. 2001 Jan;21(1):343-53.
12415108	Wong CW, McNally C, Nickbarg E, Komm BS, Cheskis BJ: Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):14783-8. Epub 2002 Nov 1.
8769313	Mosselman S, Polman J, Dijkema R: ER beta: identification and characterization of a novel human estrogen receptor. FEBS Lett. 1996 Aug 19;392(1):49-53.
9267036	Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM: Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell. 1997 Aug 8;90(3):569-80.
9325313	Pace P, Taylor J, Suntharalingam S, Coombes RC, Ali S: Human estrogen receptor beta binds DNA in a manner similar to and dimerizes with estrogen receptor alpha. J Biol Chem. 1997 Oct 10;272(41):25832-8.
9473491	Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, Ouchi Y, Muramatsu M: The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun. 1998 Feb 4;243(1):122-6.
9636657	Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM, Willson TM: Cloning and characterization of human estrogen receptor beta isoforms. Biochem Biophys Res Commun. 1998 Jun 9;247(1):75-8.
9671811	Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y, Muramatsu M: Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor ofestrogen action in human. Nucleic Acids Res. 1998 Aug 1;26(15):3505-12.
9685228	Lu B, Leygue E, Dotzlaw H, Murphy LJ, Murphy LC, Watson PH: Estrogen receptor-beta mRNA variants in human and murine tissues. Mol Cell Endocrinol. 1998 Mar 16;138(1-2):199-203.

# Drug_Target_4_HGNC_ID:
HGNC:3468

# Drug_Target_4_HPRD_ID:
03390

# Drug_Target_4_ID:
869

# Drug_Target_4_Locus:
14q23.2

# Drug_Target_4_Molecular_Weight:
59217

# Drug_Target_4_Name:
Estrogen receptor beta

# Drug_Target_4_Number_of_Residues:
530

# Drug_Target_4_PDB_ID:
1QKM

# Drug_Target_4_Pathway:
Not Available

# Drug_Target_4_Pfam_Domain_Function:
PF00104	Hormone_recep
PF00105	zf-C4

# Drug_Target_4_Protein_Sequence:
>Estrogen receptor beta
MDIKNSPSSLNSPSSYNCSQSILPLEHGSIYIPSSYVDSHHEYPAMTFYSPAVMNYSIPS
NVTNLEGGPGRQTTSPNVLWPTPGHLSPLVVHRQLSHLYAEPQKSPWCEARSLEHTLPVN
RETLKRKVSGNRCASPVTGPGSKRDAHFCAVCSDYASGYHYGVWSCEGCKAFFKRSIQGH
NDYICPATNQCTIDKNRRKSCQACRLRKCYEVGMVKCGSRRERCGYRLVRRQRSADEQLH
CAGKAKRSGGHAPRVRELLLDALSPEQLVLTLLEAEPPHVLISRPSAPFTEASMMMSLTK
LADKELVHMISWAKKIPGFVELSLFDQVRLLESCWMEVLMMGLMWRSIDHPGKLIFAPDL
VLDRDEGKCVEGILEIFDMLLATTSRFRELKLQHKEYLCVKAMILLNSSMYPLVTATQDA
DSSRKLAHLLNAVTDALVWVIAKSGISSQQQSMRLANLLMLLSHVRHASNKGMEHLLNMK
CKNVVPVYDLLLEMLNAHVLRGCKSSITGSECSPAEDSKSKEGSQNPQSQ

# Drug_Target_4_Reaction:
Not Available

# Drug_Target_4_Signals:
None

# Drug_Target_4_Specific_Function:
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner. Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA- binding by ESR1 and ESR2 is rapidly lost at 37 degrees Celsius in the absence of ligand while in the presence of 17 beta-estradiol and 4-hydroxy-tamoxifen loss in DNA-binding at elevated temperature is more gradual

# Drug_Target_4_SwissProt_ID:
Q92731

# Drug_Target_4_SwissProt_Name:
ESR2_HUMAN

# Drug_Target_4_Synonyms:
ER-beta

# Drug_Target_4_Theoretical_pI:
8.55

# Drug_Target_4_Transmembrane_Regions:
None

#END_DRUGCARD DB01196
